These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

207 related articles for article (PubMed ID: 35905624)

  • 1. Epigenomic interplay in tumor heterogeneity: Potential of epidrugs as adjunct therapy.
    Rath S; Chakraborty D; Pradhan J; Imran Khan M; Dandapat J
    Cytokine; 2022 Sep; 157():155967. PubMed ID: 35905624
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Intra-tumor heterogeneity from a cancer stem cell perspective.
    Prasetyanti PR; Medema JP
    Mol Cancer; 2017 Feb; 16(1):41. PubMed ID: 28209166
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Addressing intra-tumoral heterogeneity and therapy resistance.
    Rybinski B; Yun K
    Oncotarget; 2016 Nov; 7(44):72322-72342. PubMed ID: 27608848
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Epidrugs: targeting epigenetic marks in cancer treatment.
    Miranda Furtado CL; Dos Santos Luciano MC; Silva Santos RD; Furtado GP; Moraes MO; Pessoa C
    Epigenetics; 2019 Dec; 14(12):1164-1176. PubMed ID: 31282279
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Stem cell programs in cancer initiation, progression, and therapy resistance.
    Huang T; Song X; Xu D; Tiek D; Goenka A; Wu B; Sastry N; Hu B; Cheng SY
    Theranostics; 2020; 10(19):8721-8743. PubMed ID: 32754274
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The Role of Epigenetic Modifications in Human Cancers and the Use of Natural Compounds as Epidrugs: Mechanistic Pathways and Pharmacodynamic Actions.
    Bouyahya A; Mechchate H; Oumeslakht L; Zeouk I; Aboulaghras S; Balahbib A; Zengin G; Kamal MA; Gallo M; Montesano D; El Omari N
    Biomolecules; 2022 Feb; 12(3):. PubMed ID: 35327559
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Intratumoral Heterogeneity of the Epigenome.
    Mazor T; Pankov A; Song JS; Costello JF
    Cancer Cell; 2016 Apr; 29(4):440-451. PubMed ID: 27070699
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Metabolic Ink Lactate Modulates Epigenomic Landscape: A Concerted Role of Pro-tumor Microenvironment and Macroenvironment During Carcinogenesis.
    Sharma NK; Pal JK
    Curr Mol Med; 2021; 21(3):177-181. PubMed ID: 32436828
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Plasticity of Cancer Stem Cell: Origin and Role in Disease Progression and Therapy Resistance.
    Das PK; Pillai S; Rakib MA; Khanam JA; Gopalan V; Lam AKY; Islam F
    Stem Cell Rev Rep; 2020 Apr; 16(2):397-412. PubMed ID: 31965409
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cancer stem cells and tumor heterogeneity: Deciphering the role in tumor progression and metastasis.
    Kapoor-Narula U; Lenka N
    Cytokine; 2022 Sep; 157():155968. PubMed ID: 35872504
    [TBL] [Abstract][Full Text] [Related]  

  • 11. epihet for intra-tumoral epigenetic heterogeneity analysis and visualization.
    Chen X; Ashoor H; Musich R; Wang J; Zhang M; Zhang C; Lu M; Li S
    Sci Rep; 2021 Jan; 11(1):376. PubMed ID: 33432081
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cancer stem cell heterogeneity: origin and new perspectives on CSC targeting.
    Eun K; Ham SW; Kim H
    BMB Rep; 2017 Mar; 50(3):117-125. PubMed ID: 27998397
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Epigenetic targeting of cancer stem cells by polyphenols (cancer stem cells targeting).
    Ghasemi S; Xu S; Nabavi SM; Amirkhani MA; Sureda A; Tejada S; Lorigooini Z
    Phytother Res; 2021 Jul; 35(7):3649-3664. PubMed ID: 33619811
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Tumoral heterogeneity in neuroblastoma.
    Gomez RL; Ibragimova S; Ramachandran R; Philpott A; Ali FR
    Biochim Biophys Acta Rev Cancer; 2022 Nov; 1877(6):188805. PubMed ID: 36162542
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Insights into new mechanisms and models of cancer stem cell multidrug resistance.
    Garcia-Mayea Y; Mir C; Masson F; Paciucci R; LLeonart ME
    Semin Cancer Biol; 2020 Feb; 60():166-180. PubMed ID: 31369817
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Single-cell sequencing technology applied to epigenetics for the study of tumor heterogeneity.
    Hu Y; Shen F; Yang X; Han T; Long Z; Wen J; Huang J; Shen J; Guo Q
    Clin Epigenetics; 2023 Oct; 15(1):161. PubMed ID: 37821906
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Towards a more precise therapy in cancer: Exploring epigenetic complexity.
    Cossío FP; Esteller M; Berdasco M
    Curr Opin Chem Biol; 2020 Aug; 57():41-49. PubMed ID: 32480315
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Glioblastoma-initiating cell heterogeneity generated by the cell-of-origin, genetic/epigenetic mutation and microenvironment.
    Kondo T
    Semin Cancer Biol; 2022 Jul; 82():176-183. PubMed ID: 33453403
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Epigenetic regulation of cancer stem cells: Shedding light on the refractory/relapsed cancers.
    Xu L; Zhang J; Sun J; Hou K; Yang C; Guo Y; Liu X; Kalvakolanu DV; Zhang L; Guo B
    Biochem Pharmacol; 2022 Aug; 202():115110. PubMed ID: 35640714
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Progress and promises of epigenetic drugs and epigenetic diets in cancer prevention and therapy: A clinical update.
    Mondal P; Natesh J; Penta D; Meeran SM
    Semin Cancer Biol; 2022 Aug; 83():503-522. PubMed ID: 33309850
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.